The therapeutic landscape for Type 2 Diabetes Mellitus (T2DM) and associated cardiovascular conditions has been revolutionized by Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors. Primarily represented by Empagliflozin, Dapagliflozin, and Canagliflozin,Market this drug class has transitioned from simple glucose-lowering agents to essential treatments for Heart Failure (HF) and Chroni... https://www.databridgemarketresearch.com/